These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38964633)

  • 1. CLADIN- CLADribine and INnate immune response in multiple sclerosis - A phase IV prospective study.
    Monif M; Sequeira RP; Muscat A; Stuckey S; Sanfilippo PG; Minh V; Loftus N; Voo V; Fazzolari K; Moss M; Maltby VE; Nguyen AL; Wesselingh R; Seery N; Nesbitt C; Baker J; Dwyer C; Taylor L; Rath L; Van der Walt A; Marriott M; Kalincik T; Lechner-Scott J; O'Brien TJ; Butzkueven H
    Clin Immunol; 2024 Aug; 265():110304. PubMed ID: 38964633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients - An
    Dobreanu M; Manu DR; Mănescu IB; Gabor MR; Huţanu A; Bărcuţean L; Bălaşa R
    Front Immunol; 2021; 12():743010. PubMed ID: 34970256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 in Cladribine-treated patient with multiple sclerosis.
    Haham N; Vaknin-Dembinsky A
    J Neuroimmunol; 2021 Oct; 359():577690. PubMed ID: 34390951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP; Weissert R
    Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
    Giovannoni G
    Neurotherapeutics; 2017 Oct; 14(4):874-887. PubMed ID: 29168160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cladribine tablets' potential in multiple: sclerosis treatment.
    Costello K; Sipe JC
    J Neurosci Nurs; 2008 Oct; 40(5):275-80. PubMed ID: 18856248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ
    Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cladribine for multiple sclerosis.
    Drug Ther Bull; 2018 Feb; 56(2):21-24. PubMed ID: 29449328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED
    CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T; Torkildsen Ø; Myhr KM
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study.
    Rejdak K; Stelmasiak Z; Grieb P
    Mult Scler Relat Disord; 2019 Jan; 27():117-120. PubMed ID: 30368223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
    Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
    Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
    Rammohan K; Coyle PK; Sylvester E; Galazka A; Dangond F; Grosso M; Leist TP
    Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B; Guerreiro R; Costa J; Miguel LS
    J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
    [No Abstract]   [Full Text] [Related]  

  • 17. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
    Bartosik-Psujek H; Belniak E; Mitosek-Szewczyk K; Dobosz B; Stelmasiak Z
    Acta Neurol Scand; 2004 Jun; 109(6):390-2. PubMed ID: 15147461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.